IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-18 DOI: 10.1080/17501911.2026.2735721

Ensie Sadat Mirsharif, Abdolrahman Rostamian, Mohammadreza Salehi, Nayere Askari, Tooba Ghazanfari

{"title":"Evaluation of mRNA expression and DNA methylation status of immune checkpoints in the peripheral blood of COVID-19 patients.","authors":"Ensie Sadat Mirsharif, Abdolrahman Rostamian, Mohammadreza Salehi, Nayere Askari, Tooba Ghazanfari","doi":"10.1080/17501911.2026.2735721","DOIUrl":"https://doi.org/10.1080/17501911.2026.2735721","url":null,"abstract":"Background: COVID-19 immunopathology involves dysregulated immune responses, partly mediated by inhibitory immune checkpoints (ICs). Epigenetic mechanisms, particularly DNA methylation by DNA methyltransferases (DNMTs), regulate gene expression. However, the interplay between IC transcription, promoter methylation, and DNMT expression across disease severities remains unclear.Research design and methods: This cross-sectional study enrolled 208 COVID-19 patients (mild to critical) and 93 healthy controls. mRNA expression of PDCD-1, HAVCR-2, LAG-3, CTLA-4, DNMT-1, DNMT-3a, and DNMT-3b was measured by RT qPCR after covariate adjustment. Promoter methylation of the four IC genes was assessed by MS-HRM in 90 patients and 24 controls.Results: COVID-19 patients showed significantly lower mRNA levels of PDCD-1, LAG-3, and CTLA-4 versus controls, with further reductions in hospitalized, ICU-admitted, and non-survivor subgroups. DNMT-1, DNMT-3a, and DNMT-3b transcripts were also markedly decreased. No significant methylation changes were observed for any of the four IC genes after FDR correction (all q >0.05).Conclusions: Reduced DNMT transcripts suggest possible global hypomethylation, but no significant promoter methylation changes were detected for the IC genes examined. Whole-blood analysis and lack of protein/functional validation limit interpretation. This exploratory study provides a foundation for future cell-specific and prospective investigations into epigenetic-transcriptional crosstalk in COVID-19.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-14"},"PeriodicalIF":3.1,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Xeroderma Pigmentosum group F (XPF) with epigenetic regulation of T helper cell differentiation in coronary artery disease-associated prostate cancer. 着色性干皮病F组（XPF）与冠状动脉疾病相关前列腺癌中辅助性T细胞分化的表观遗传调控的关系

IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-13 DOI: 10.1080/17501911.2026.2746944

Anisha Singha Deo, Shrijana P, Shreya Karun, Sruthika S U, Oishi Mukherjee, Melvin George, Koustav Sarkar

{"title":"Association of Xeroderma Pigmentosum group F (XPF) with epigenetic regulation of T helper cell differentiation in coronary artery disease-associated prostate cancer.","authors":"Anisha Singha Deo, Shrijana P, Shreya Karun, Sruthika S U, Oishi Mukherjee, Melvin George, Koustav Sarkar","doi":"10.1080/17501911.2026.2746944","DOIUrl":"https://doi.org/10.1080/17501911.2026.2746944","url":null,"abstract":"Background: Coronary artery disease (CAD) and prostate cancer share common genetic and epigenetic risk factors. Xeroderma Pigmentosum group F (XPF), a DNA repair endonuclease, has been implicated in genomic stability and epigenetic regulation. This study investigated the association between XPF expression and epigenetic changes during T helper (TH) cell differentiation in CAD-associated prostate cancer (CAD-PC).Research design and methods: CD4+ T cells isolated from healthy controls and CAD-PC patients were subjected to CRISPR/Cas9-mediated XPF knockout or overexpression. TH cell differentiation, chromatin enrichment, global m6A RNA methylation, DNA methylation, R-loop formation, and tumor cell cytotoxicity were evaluated using molecular and functional assays.Results: XPF overexpression was associated with increased TH1 differentiation and elevated expression of XPF and TP53, whereas TH2, TH17, and Treg-associated markers were reduced. Increased enrichment of XPF and H3K4me3, together with reduced HDAC1, γH2A.X, and H3K27me3 enrichment, was observed at the TBX21 and IFNG loci. XPF overexpression was also associated with increased global m6A RNA methylation, reduced DNA methylation at TH1-associated loci, decreased R-loop accumulation, and enhanced tumor cell cytotoxicity in vitro.Conclusion: These findings suggest that XPF expression is associated with a TH1-skewed epigenetic and immune profile in CAD-PC. However, the absence of disease-specific comparison groups and in vivo validation limits mechanistic interpretation, and further studies are required to establish causality. The present findings demonstrate an association between XPF and the observed TH1-associated epigenetic changes.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-13"},"PeriodicalIF":3.1,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-cohort DNA methylation analysis shows CpG island promoter hypermethylation features associated with cervical lesion grade. 跨队列DNA甲基化分析显示CpG岛启动子高甲基化特征与宫颈病变等级相关。

IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-13 DOI: 10.1080/17501911.2026.2746945

Yushan Xia, Jie Wang, Liyan Duan, Ya Li, Guangming Li, Yu Wang, Wei Zhang

{"title":"Cross-cohort DNA methylation analysis shows CpG island promoter hypermethylation features associated with cervical lesion grade.","authors":"Yushan Xia, Jie Wang, Liyan Duan, Ya Li, Guangming Li, Yu Wang, Wei Zhang","doi":"10.1080/17501911.2026.2746945","DOIUrl":"https://doi.org/10.1080/17501911.2026.2746945","url":null,"abstract":"Background: Cervical lesion progression is accompanied by epigenomic alterations, but reproducible methylation features across public cohorts require cautious re-analysis.Study design and methods: We performed a secondary analysis of public Illumina 450K methylation cohorts: GSE46306 as discovery (20 normal, 17 CIN3, six carcinoma), GSE99511 and GSE186835 as validation, and TCGA-CESC tumors for methylation-RNA expression association. Shared autosomal CpGs were screened for monotonic grade-associated change, cross-cohort directional consistency, promoter annotation, regional aggregation, sample-level score performance, and tumor expression correlation. No intervention, dose, treatment regimen, blinding, or safety outcome was involved.Results: Among 340, 248 shared autosomal CpGs, 3, 008 met robust cross-cohort criteria, including 2, 991 hypermethylated and 17 hypomethylated sites. Robust sites mapped to 628 promoter genes and 660 multi-CpG DMR-like regions. A fixed 200-CpG score yielded AUCs of 0.733-0.963 for CIN3 or worse versus controls and 0.971-0.988 for cancer versus non-cancer. In TCGA-CESC, 394 of 610 detectable robust promoter genes showed significant negative methylation-expression correlations.Conclusions: The reanalysis supports reproducible CpG island and promoter hypermethylation features associated with cervical lesion grade, but processed data, cohort heterogeneity, cross-sectional tumor associations, and absence of prospective validation limit interpretation to candidate atlas generation.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-10"},"PeriodicalIF":3.1,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What can epigenomics tell us about prostate cancer disparities? 表观基因组学能告诉我们前列腺癌的差异吗？

IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-11 DOI: 10.1080/17501911.2026.2745488

Carmen Ortiz-Sánchez, Jong Y Park

引用次数: 0

ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer: an integrated transcriptomic, epigenetic and in vitro analysis. ATP1A2作为乳腺癌亚型相关的候选预后生物标志物：综合转录组学、表观遗传学和体外分析

IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-08 DOI: 10.1080/17501911.2026.2744072

Daniel Rodrigues de Bastos, Renan Gomes do Nascimento, Maiza Vitoria Aguiar Silva Oliveira, Sandra Gonzalez L, Marilaura Chamorro, Ricardo Cesar Cintra

{"title":"ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer: an integrated transcriptomic, epigenetic and in vitro analysis.","authors":"Daniel Rodrigues de Bastos, Renan Gomes do Nascimento, Maiza Vitoria Aguiar Silva Oliveira, Sandra Gonzalez L, Marilaura Chamorro, Ricardo Cesar Cintra","doi":"10.1080/17501911.2026.2744072","DOIUrl":"https://doi.org/10.1080/17501911.2026.2744072","url":null,"abstract":"Background: To evaluate ATP1A2 as a subtype-associated candidate prognostic biomarker in breast cancer by integrating transcriptomic, epigenetic, immune, survival, and in vitro expression analyses.Research design and methods: ATP1A2 mRNA expression was analyzed using TCGA-BRCA data from 1,087 patients and compared across clinicopathological and molecular features. DNA methylation was evaluated across twelve ATP1A2 CpG sites, and RT-qPCR was performed in breast cancer cell lines representing luminal, HER2-enriched, and triple-negative models under basal conditions and after therapeutic exposure.Results: ATP1A2 expression was reduced in breast tumors compared with tumor-adjacent normal breast tissue and followed a subtype-dependent pattern, with the lowest levels in basal-like tumors and the highest in luminal A and normal-like tumors. Low ATP1A2 expression was associated with aggressive clinicopathological features, hormone receptor negativity, HER2 positivity, and non-luminal subtypes. High ATP1A2 expression predicted improved overall and disease-free survival and remained independently associated with overall survival. Basal-like tumors displayed ATP1A2 amplification despite reduced mRNA expression, suggesting possible passenger-gene behavior within the 1q21-q23 amplicon. Methylation and immune analyses suggested epigenetic and microenvironmental influences, whereas in vitro assays showed treatment-associated transcriptional modulation.Conclusions: ATP1A2 s associated with breast cancer subtype and independently predicts overall survival, warranting further independent validation.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-15"},"PeriodicalIF":3.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell-free DNA fragmentomics: from chromatin biology to clinical stratification. 无细胞DNA片段组学：从染色质生物学到临床分层。

IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-03 DOI: 10.1080/17501911.2026.2740396

Tien-Dung Bui, Minh-Thu Phung, Teh-Ying Chou, Nguyen Quoc Khanh Le

{"title":"Cell-free DNA fragmentomics: from chromatin biology to clinical stratification.","authors":"Tien-Dung Bui, Minh-Thu Phung, Teh-Ying Chou, Nguyen Quoc Khanh Le","doi":"10.1080/17501911.2026.2740396","DOIUrl":"https://doi.org/10.1080/17501911.2026.2740396","url":null,"abstract":"Plasma cell-free DNA (cfDNA) is fragmented nonrandomly, reflecting the chromatin architecture of its source cells and the nucleases that process it. The fragmentome can therefore provide an indirect readout of cellular regulatory state. This review examines how DNA methylation, chromatin accessibility, nucleosome positioning, protein occupancy, and nuclease activity shape cfDNA fragmentation and considers their implications for oncology. We organize fragmentomic measurements into four classes: coverage and protection, fragment size, fragment-end properties, and diversity and entropy metrics. We discuss the genomic contexts in which these features are informative, including repetitive and transposable elements, and compare platforms by sequencing requirements, feature portability, and the fragment populations captured by different library chemistries. We then review applications in cancer screening, tissue-of-origin inference, molecular subtyping, prognosis, minimal residual disease detection, and treatment response monitoring. A central challenge for clinical translation is attributing fragmentomic changes to their tissue of origin.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-13"},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of linker histone H1.2 in tumor progression, resistance, and clinical translation. 连接蛋白H1.2在肿瘤进展、耐药和临床翻译中的作用

IF 3.1 4区医学

Epigenomics Pub Date : 2026-10-01 DOI: 10.1080/17501911.2026.2740944

Jiayang Zhou, Jiajian Shi, Ling Zheng, Kun Huang, Yangkai Li

{"title":"The role of linker histone H1.2 in tumor progression, resistance, and clinical translation.","authors":"Jiayang Zhou, Jiajian Shi, Ling Zheng, Kun Huang, Yangkai Li","doi":"10.1080/17501911.2026.2740944","DOIUrl":"https://doi.org/10.1080/17501911.2026.2740944","url":null,"abstract":"Linker histone H1 has traditionally been regarded as a structural scaffold that stabilizes higher-order chromatin organization. Recent evidence, however, indicates that H1 variants are dynamic chromatin regulators with variant-specific functions in cancer. Among them, H1.2, encoded by H1-2 (formerly HIST1H1C), has emerged as a context-dependent regulator of chromatin compaction, DNA damage signaling, transcription, stress adaptation, and cell fate. This review summarizes the structural and post-translational features of H1.2 and examines how these properties contribute to tumor progression, invasion, metastasis, and therapeutic resistance. We focus on H1.2-mediated control of the cell cycle, Polycomb-dependent gene silencing, oncogenic transcriptional programs, genotoxic stress tolerance, redox-metabolic adaptation, apoptosis evasion, epithelial-mesenchymal transition-associated drug tolerance, and immune microenvironment remodeling. We also evaluate H1.2 as a tissue-based or circulating biomarker, a post-translational modification-based functional readout, and a guide for biomarker-driven combination therapy. Although direct pharmacological targeting remains preliminary, isoform-selective modulation and interventions targeting H1.2-associated regulatory pathways may expand its future therapeutic potential in precision oncology.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-17"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of cancer therapy? Integrating oncolytic adenoviruses with epigetic modulation. 癌症治疗的未来？整合溶瘤腺病毒与表观遗传调节。

IF 3.1 4区医学

Epigenomics Pub Date : 2026-09-29 DOI: 10.1080/17501911.2026.2739787

Saira Zulfiqar, Xiaoyan Wang, Baofu Chen, Yigang Wang

{"title":"The future of cancer therapy? Integrating oncolytic adenoviruses with epigetic modulation.","authors":"Saira Zulfiqar, Xiaoyan Wang, Baofu Chen, Yigang Wang","doi":"10.1080/17501911.2026.2739787","DOIUrl":"https://doi.org/10.1080/17501911.2026.2739787","url":null,"abstract":"Therapeutic resistance remains a defining limitation in the management of advanced solid tumors, where conventional modalities including chemotherapy, radiotherapy, and immune checkpoint blockade often fail to achieve durable responses. Oncolytic adenoviruses (OAds) have emerged as tumor-selective and immunogenic platforms capable of inducing direct oncolytic and systemic antitumor immunity. However, their clinical efficacy is frequently constrained by intrinsic tumor resistance mechanisms, including impaired viral entry, antiviral immune responses, and immunologically \"cold\" tumor microenvironments. Epigenetic modulation represents a promising strategy to overcome these barriers by reprogramming chromatin accessibility, restoring antigen presentation, and enhancing viral permissiveness. This review explores the mechanistic and translational rationale for integrating OAds with epigenetic therapies, highlighting preclinical and clinical evidence supporting synergistic interactions. We further discuss the implications of this combinatorial approach for precision oncology and its potential to redefine therapeutic paradigms in resistant malignancies.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-14"},"PeriodicalIF":3.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twin study: genotype-dependent epigenetic factors associated with HbA1c levels. 双胞胎研究：与HbA1c水平相关的基因型依赖性表观遗传因素

IF 3.1 4区医学

Epigenomics Pub Date : 2026-09-29 DOI: 10.1080/17501911.2026.2738328

Hinako Hashimoto, Yuya Arakawa, Ritsuko Ozaki, Mika Hasegawa, Shiho Kato, Saho Mori, Saki Yoshioka, Hiromichi Ueda, Osaka Twin Research Group, Mikio Watanabe

{"title":"Twin study: genotype-dependent epigenetic factors associated with HbA1c levels.","authors":"Hinako Hashimoto, Yuya Arakawa, Ritsuko Ozaki, Mika Hasegawa, Shiho Kato, Saho Mori, Saki Yoshioka, Hiromichi Ueda, Osaka Twin Research Group, Mikio Watanabe","doi":"10.1080/17501911.2026.2738328","DOIUrl":"https://doi.org/10.1080/17501911.2026.2738328","url":null,"abstract":"Background: Hemoglobin A1c (HbA1c) is a biomarker for diabetes mellitus. Twin studies suggest substantial heritability, but the molecular basis of non-genetic variation remains unclear. We aimed to explore genetic and epigenetic factors associated with HbA1c through multi-omics analysis of monozygotic twins.Materials and methods: A total of 285 monozygotic and 27 dizygotic twin pairs were enrolled in Japan. Genome-wide single-nucleotide variant (SNV) genotyping, DNA methylation profiling, and RNA sequencing were performed. Based on HbA1c levels, twin pairs were classified as high concordant, low concordant, or discordant. Structural equation modeling estimated heritability, and GWAS, within-pair methylation comparisons, and expression-methylation correlation analyses were conducted.Results: Our analysis estimated that genetic factors accounted for 68% of the phenotypic variance in covariate-adjusted HbA1c. Within-pair methylation comparisons revealed several suggestive CpG sites associated with HbA1c variation. GWAS revealed one suggestive SNV associated with higher HbA1c and three SNVs potentially associated with susceptibility to HbA1c variation. Genotype-stratified analyses showed exploratory genetic background-dependent methylation changes at CpG sites, some of which correlated with gene expression.Conclusion: This study estimated the heritability of adjusted HbA1c and revealed preliminary genetic and epigenetic signals in Japanese twins. Further studies are needed to confirm their biological and clinical significance.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-11"},"PeriodicalIF":3.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic age acceleration is not strongly associated with cardiorespiratory fitness in heart failure: a pilot study. 一项初步研究表明，表观遗传年龄加速与心力衰竭患者的心肺健康没有很强的相关性。

IF 3.1 4区医学

Epigenomics Pub Date : 2026-09-01 Epub Date: 2026-09-17 DOI: 10.1080/17501911.2026.2732421

Sina Mahdiani, Azita H Talasaz, Ola AlAzzeh, Benjamin Van Tassell, Joseph L McClay

{"title":"Epigenetic age acceleration is not strongly associated with cardiorespiratory fitness in heart failure: a pilot study.","authors":"Sina Mahdiani, Azita H Talasaz, Ola AlAzzeh, Benjamin Van Tassell, Joseph L McClay","doi":"10.1080/17501911.2026.2732421","DOIUrl":"10.1080/17501911.2026.2732421","url":null,"abstract":"Background: In heart failure (HF), standard measures such as left ventricular ejection fraction and cardiopulmonary exercise testing incompletely capture interindividual differences in disease status or prognosis. DNA methylation (DNAm) epigenetic clocks, which estimate biological age and epigenetic age acceleration (EAA), may provide complementary insight into cardiorespiratory fitness and systemic aging in HF.Research design and methods: We analyzed peripheral blood DNAm from fourteen patients enrolled in REDHART2, a clinical trial of interleukin-1 blockade following hospitalization for acute systolic HF. Genome-wide DNAm was assayed using Illumina EPIC arrays and several clocks were applied to these data. Associations between biological age or EAA and cardiorespiratory fitness measures, inflammatory markers, and clinical parameters were evaluated.Results: All epigenetic clocks demonstrated moderate to strong correlations with chronological age. Biological age was consistently associated with measures of cardiorespiratory fitness, particularly oxygen consumption normalized to fat free mass (VO2_FFM). However, chronological age showed similar associations, and biological age did not significantly improve prediction of VO2 parameters beyond chronological age alone. EAA was not significantly associated with cardiorespiratory fitness for any clock.Conclusions: In this pilot study, neither biological age nor EAA provided significant predictive value beyond chronological age for cardiorespiratory fitness in patients with HF.Clinical trial registration number: NCT03797001.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1101-1112"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenomics最新文献